Curis Inc. (CRIS)’s Financial Results Comparing With Anchiano Therapeutics Ltd (NASDAQ:ANCN)

Curis Inc. (NASDAQ:CRIS) and Anchiano Therapeutics Ltd (NASDAQ:ANCN) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Curis Inc. 2 7.45 N/A -0.96 0.00
Anchiano Therapeutics Ltd 5 0.00 N/A -8.38 0.00

Table 1 highlights Curis Inc. and Anchiano Therapeutics Ltd’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Curis Inc. and Anchiano Therapeutics Ltd.

Net Margins Return on Equity Return on Assets
Curis Inc. 0.00% 0% -66.7%
Anchiano Therapeutics Ltd 0.00% 0% 0%

Analyst Ratings

Curis Inc. and Anchiano Therapeutics Ltd Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Curis Inc. 0 0 0 0.00
Anchiano Therapeutics Ltd 0 0 1 3.00

Competitively Anchiano Therapeutics Ltd has a consensus target price of $12, with potential upside of 374.31%.

Insider & Institutional Ownership

Institutional investors owned 24.7% of Curis Inc. shares and 0.75% of Anchiano Therapeutics Ltd shares. 17.28% are Curis Inc.’s share owned by insiders. Comparatively, 23.87% are Anchiano Therapeutics Ltd’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Curis Inc. -5.42% 24.04% 24.04% 97.39% 36.75% 229.08%
Anchiano Therapeutics Ltd -22.25% -33.11% -48.79% 0% 0% -72.5%

For the past year Curis Inc. had bullish trend while Anchiano Therapeutics Ltd had bearish trend.

Summary

Curis Inc. beats on 4 of the 7 factors Anchiano Therapeutics Ltd.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.